Isoniazid Preventive Therapy for Tuberculosis in People Living with HIV: A Cross Sectional Study in Butebo, Uganda
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Despite evidence that isoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) disease among People Living with Human Immunodeficiency Virus (PLHIV), uptake of IPT is low in many resource-limited settings. This study determined the level of IPT uptake and its associated factors amongst PLHIV. Materials and methods: This was a retrospective quantitative study amongst PLHIV who do not have active TB and enrolled in 2019 - 2020 for anti-retroviral therapy (ART) in Butebo district, Uganda. Data related to demographic factors (age, sex, religion, marital status, employment status, education level, area of residence, household density), health facility factors (pre-IPT counseling), community factors [distance from Health Center (H/C), incurred costs to reach H/C], and IPT drug-related factors [frequency of Isoniazid (INH) refill, INH stock-outs] were collected from four health facilities using a checklist. The data was analyzed into descriptive statistics and relationships determined using Chi-square tests. Results: Among eligible PLHIV (272), 34.2% achieved IPT uptake. The mean duration between HIV diagnosis and the start of IPT was 4.31 years, with IPT Uptake among males (37.0%), females (32.8%), married (39.5%), and Christians (35.4%). Factors that affect the rate of IPT uptake include employment, education, residence, costs to reach H/C, and pre-IPT counseling. The IPT completion rate was 97.8%. All the cases who had regular INH refill completed IPT compared to 60.0% with the irregular refill, while 97.8% did not experience INH stock-outs and completed IPT. Conclusion: Pre-IPT counseling was the most significant contributing factor for IPT uptake. IPT uptake may be scaled up by integrating IPT services in routine HIV care, enhancing counseling for IPT and supervision and monitoring, training of health workers, and improving logistical supplies at the health centers.
Abstract
Background: Despite evidence that isoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) disease among People Living with Human Immunodeficiency Virus (PLHIV), uptake of IPT is low in many resource-limited settings. This study determined the level of IPT uptake and its associated factors amongst PLHIV. Materials and methods: This was a retrospective quantitative study amongst PLHIV who do not have active TB and enrolled in 2019 - 2020 for anti-retroviral therapy (ART) in Butebo district, Uganda. Data related to demographic factors (age, sex, religion, marital status, employment status, education level, area of residence, household density), health facility factors (pre-IPT counseling), community factors [distance from Health Center (H/C), incurred costs to reach H/C], and IPT drug-related factors [frequency of Isoniazid (INH) refill, INH stock-outs] were collected from four health facilities using a checklist. The data was analyzed into descriptive statistics and relationships determined using Chi-square tests. Results: Among eligible PLHIV (272), 34.2% achieved IPT uptake. The mean duration between HIV diagnosis and the start of IPT was 4.31 years, with IPT Uptake among males (37.0%), females (32.8%), married (39.5%), and Christians (35.4%). Factors that affect the rate of IPT uptake include employment, education, residence, costs to reach H/C, and pre-IPT counseling. The IPT completion rate was 97.8%. All the cases who had regular INH refill completed IPT compared to 60.0% with the irregular refill, while 97.8% did not experience INH stock-outs and completed IPT. Conclusion: Pre-IPT counseling was the most significant contributing factor for IPT uptake. IPT uptake may be scaled up by integrating IPT services in routine HIV care, enhancing counseling for IPT and supervision and monitoring, training of health workers, and improving logistical supplies at the health centers.
참고문헌 (19)
- Sullivan BJ, "Barriers to initiating tuberculosis treatment in sub-Saharan Africa : a systematic review focused on children and youth", Glob Health Action, 10, pp.1290317~ (2017)
- Daley CL, "The global fight against tuberculosis", Thorac Surg Clin, 29, pp.19~25 (2019)
- "Global Tuberculosis Report 2019"[URL]
- Wambiya EOA, "Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya : a qualitative study", BMJ Open, 8, pp.e024286~ (2018)
- "Uganda country profile"[URL]
- Lönnroth K, "The WHO’s new End TB Strategy in the post-2015 era of the Sustainable Development Goals", Trans R Soc Trop Med Hyg, 110, pp.148~150 (2016)
- Getahun H, "Implementation of isoniazid preventive therapy for people living with HIV worldwide : barriers and solutions", AIDS, 24(Suppl 5), pp.S57~S65 (2010)
- Sensalire S, "A prospective cohort study of outcomes for isoniazid prevention therapy : a nested study from a national QI collaborative in Uganda", AIDS Res Ther, 17, pp.28~ (2020)
- Shivaramakrishna HR, "Isoniazid preventive treatment in children in two districts of South India : does practice follow policy?", Int J Tuberc Lung Dis, 18, pp.919~924 (2014)
- Kagujje M, "Implementation of isoniazid preventive therapy in people living with HIV in Zambia : challenges and lessons", BMC Public Health, 19, pp.1329~ (2019)
- Singh AR, "Isoniazid preventive therapy among children living with tuberculosis patients: Is it working? a mixed-method study from Bhopal, India", J Trop Pediatr, 63, pp.274~285 (2017)
- Osman M, "Routine programmatic delivery of isoniazid preventive therapy to children in Cape Town, South Africa", Public Health Action, 3, pp.199~203 (2013)
- Claessens NJ, "Screening childhood contacts of patients with smear-positive pulmonary tuberculosis in Malawi", Int J Tuberc Lung Dis, 6, pp.362~364 (2002)
- Hall C, "Challenges to delivery of isoniazid preventive therapy in a cohort of children exposed to tuberculosis in Timor-Leste", Trop Med Int Health, 20, pp.730~736 (2015)
- Tadesse Y, "Uptake of isoniazid preventive therapy among under-five Children : TB contact investigation as an entry point", PLoS One, 11, pp.e0155525~ (2016)
- Egere U, "Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia", Public Health Action, 6, pp.226~231 (2016)
- Birungi FM, "Assessment of the isoniazid preventive therapy uptake and associated characteristics : A cross-sectional study", Tuberc Res Treat, 2018, pp.8690714~ (2018)
- Adjobimey M, "Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin", Int J Tuberc Lung Dis, 20, pp.1055~1059 (2016)